Literature DB >> 6496328

Cardiac involvement in myotonic muscular dystrophy (Steinert's disease): a prospective study of 25 patients.

J K Perloff, W G Stevenson, N K Roberts, W Cabeen, J Weiss.   

Abstract

The presence, degree and frequency of disorders of cardiac conduction and rhythm and of regional or global myocardial dystrophy or myotonia have not previously been studied prospectively and systematically in the same population of patients with myotonic dystrophy. Accordingly, 25 adults with classic Steinert's disease underwent electrocardiography, 24-hour ambulatory electrocardiography, vectorcardiography, chest x-rays, echocardiography, electrophysiologic studies, and technetium-99m angiography. Clinically important cardiac manifestations of myotonic dystrophy reside in specialized tissues rather than in myocardium. Involvement is relatively specific, primarily assigned to the His-Purkinje system. The cardiac muscle disorder takes the form of dystrophy rather than myotonia, and is not selective, appearing with approximately equal distribution in all 4 chambers. Myocardial dystrophy seldom results in clinically overt ventricular failure, but may be responsible for atrial and ventricular arrhythmias. Since myotonic dystrophy is genetically transmitted, a primary biochemical defect has been proposed with complete expression of the gene toward striated muscle tissue, whether skeletal or cardiac. Specialized cardiac tissue and myocardium have close, if not identical, embryologic origins, so it is not surprising that the genetic marker affects both. Cardiac involvement is therefore an integral part of myotonic dystrophy, targeting particularly the infranodal conduction system, to a lesser extent the sinus node, and still less specifically, the myocardium.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496328     DOI: 10.1016/s0002-9149(84)80147-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Is it possible to identify infrahissian cardiac conduction abnormalities in myotonic dystrophy by non-invasive methods?

Authors:  D Babuty; L Fauchier; D Tena-Carbi; P Poret; J Leche; M Raynaud; J P Fauchier; P Cosnay
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

2.  Progressive atrioventricular conduction block in a mouse myotonic dystrophy model.

Authors:  C I Berul; C T Maguire; J Gehrmann; S Reddy
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

Review 3.  Cardiac spectroscopy: techniques, indications and clinical results.

Authors:  Meinrad Beer
Journal:  Eur Radiol       Date:  2004-03-06       Impact factor: 5.315

4.  Myotonia dystrophica--first presentation as severe left ventricular failure complicating dilated cardiomyopathy.

Authors:  L D Premawardhana; G Thirunavakarasu
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

5.  [Guidelines for heart pacemaker therapy].

Authors:  B Lemke; B Nowak; D Pfeiffer
Journal:  Z Kardiol       Date:  2005-10

6.  Electrocardiographic findings in myotonic dystrophy.

Authors:  B O Olofsson; H Forsberg; S Andersson; P Bjerle; A Henriksson; I Wedin
Journal:  Br Heart J       Date:  1988-01

7.  Cardiac involvement in congenital myotonic dystrophy.

Authors:  H Forsberg; B O Olofsson; A Eriksson; S Andersson
Journal:  Br Heart J       Date:  1990-02

Review 8.  Mitral valve prolapse associated with other disorders. Casual coincidence, common link, or fundamental genetic disturbance?

Authors:  A D Malcolm
Journal:  Br Heart J       Date:  1985-04

9.  Clinical significance of QS complexes in V1 and V2 without other electrocardiographic abnormality.

Authors:  Rex N MacAlpin
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

10.  A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters.

Authors:  H J Sugerman; J V Starkey; R Birkenhauer
Journal:  Ann Surg       Date:  1987-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.